News | June 15, 2012

Data Supports Efficacy of New Flutemetamol Imaging Agent for Detection of Amyloid Plaque

June 15, 2012 — Data presented at the Society for Nuclear Medicine (SNM) Annual Meeting shows that uptake of the investigational imaging agent [18F] flutemetamol correlates with a beta amyloid in vivo biopsy and can be quantified using a positron emission tomography (PET)-only registration method. Data from other studies show that flutemetamol (F18) uptake is inversely related to measures of cognitive function in non-demented older adults. Additionally, the flutemetamol (F18) dosimetry profile is comparable to that of most PET diagnostic radiopharmaceuticals and the biodistribution attributes in Japanese and Caucasian subjects is comparable. Flutemetamol (F18) is a PET imaging agent in development for the detection of beta amyloid, which could add value to current diagnostic tools used by physicians to evaluate neurodegenerative conditions like Alzheimer’s disease (AD). 

The accumulation of beta amyloid in the brain is believed to play a role in the degeneration of neurons in AD and is one of several pathological characteristics implicated in its development. Currently, AD is confirmed by histopathological identification of core features, including beta amyloid plaques, in postmortem brain samples. Targeted amyloid imaging agents are being studied to determine their ability to help physicians detect amyloid deposition in living humans.

Data from studies featured at the meeting in Miami show that:

  • In a comparison of automated quantification methods using 72 images from the flutemetamol (F18) phase 2 study, a PET-only method produced very similar results to an MR-based method using FreeSurfer. Furthermore, when applied to AIBL data, the automated PET-only method produced results that were very similar to those obtained when a trained expert manually placed regions on co-registered MRI. The results show that the automated quantification method produced accurate and robust results without further use of MRI.
  • Two phase 1 studies of flutemetamol (F18) in healthy Japanese volunteers and in subjects with probable AD showed that radiation dosimetry profiles in healthy volunteers were both comparable to those of most PET diagnostic radiopharmaceuticals and that biodistribution attributes were similar in Japanese and Caucasian populations of health volunteers and patients with probable AD.
  • In pooled analysis from four studies of 49 patients receiving flutemetamol (F18) before or after brain biopsy during shunt placement or intracranial pressure measurement, flutemetamol (F18) detected visual reads correlated with biopsy with an overall majority read sensitivity of 93 percent and specificity of 100 percent.
  • In a separate study of 11 community-dwelling non-demented older adults with subjective memory complaints, which compared the relationship between flutemetamol (F18) uptake and measures of cognitive performance (delayed memory index from RBANS), flutemetamol (F18) uptake showed a significant negative correlation when the delayed memory index was adjusted for pre-morbid IQ.

Flutemetamol (F18) is one part of a broad portfolio of diagnostic solutions that GE Healthcare is currently developing in the Alzheimer’s field. The company is taking a comprehensive approach to understanding AD through its ongoing research to uncover the causes, risks, and physical effects of the disease. GE Healthcare’s global commitment to advance clinical knowledge and provide a variety of technologies to aid in the fight against this epidemic may assist physicians in the acceleration of diagnosis and improvement of treatment decisions in all stages of the disease.

The company already offers a broad portfolio of imaging resources, which support accurate visualization of the signs of neurodegenerative diseases via state-of-the-art scanners - including MRI, PET, and CT - that deliver clear visualization of the brain. More specifically, our portfolio today includes cyclotrons and chemistry systems to manufacture PET imaging agents, PET and MR scanners to scan patients, and image analysis software to interpret the results. 

GE Healthcare has been a key contributor to the Alzheimer’s Disease Neuroimaging Initiative (ADNI) since its inception. The company also plays a primary role in PredictAD, an EU-funded research project to develop solutions to enable earlier diagnosis of AD, and in the Coalition Against Major Diseases (CAMD).

Related Content

Novel PET Tracer Clearly Identifies and Tracks Bacterial Lung Infection

Representative PET/CT images of 18F-FDS and 18F-FDG in inflamed mice. Mice were inoculated with dead K. pneumoniae (10^8 CFU/mL). Imaging was performed for days 1, 2, 3 and 4 using 18F-FDG and 18F-FDS. CT images showed clear inflammation on day 2 and day 3 with corresponding high 18F-FDG uptake on PET. No significant uptake of 18F-FDS was detected for any of those 4 days. Credit: J Li et al., University of Louisville School of Medicine, Louisville, Ky.

News | PET-CT | January 22, 2018
January 22, 2018 — Researchers at the University of Louisville, Kentucky, have demonstrated that a new...
Transpara Deep Learning Software Matches Experienced Radiologists in Mammogram Reading
News | Computer-Aided Detection Software | January 12, 2018
Deep learning and artificial intelligence improves the efficiency and accuracy of reading mammograms, according to...
Fat Distribution in Women and Men Provides Clues to Heart Attack Risk
News | Women's Health | January 11, 2018
January 11, 2018 – It’s not the amount of fat in your body but where it is stored that may increase your risk for hea
Smartphone Addiction Creates Imbalance in Brain
News | Mobile Devices | January 11, 2018
Researchers have found an imbalance in the brain chemistry of young people addicted to smartphones and the internet,...
Emergency Radiologists See Inner Toll of Opioid Use Disorders

Rates of Imaging Positivity for IV-SUDs Complications. Image courtesy of Efren J. Flores, M.D.

News | Clinical Study | January 11, 2018
January 11, 2018 – Emergency radiologists are seeing a high prevalence of patients with complications related to opio
Minimally Invasive Treatment Provides Relief from Back Pain

Lumbar spine MRI showing disc herniation and nerve root at baseline and one month after treatment

News | Interventional Radiology | January 11, 2018
The majority of patients were pain free after receiving a new image-guided pulsed radiofrequency treatment for low back...
Study Finds No Evidence that Gadolinium Causes Neurologic Harm

MR images through, A, C, E, basal ganglia and, B, D, F, posterior fossa at level of dentate nucleus. Images are shown for, A, B, control group patient 4, and the, C, D, first and, E, F, last examinations performed in contrast group patient 13. Regions of interest used in quantification of signal intensity are shown as dashed lines for globus pallidus (green), thalamus (blue), dentate nucleus (yellow), and pons (red).

News | Contrast Media | January 11, 2018
January 11, 2018 — There is no evidence that accumulation in the brain of the element gadolinium speeds cognitive dec
CT Shows Enlarged Aortas in Former Pro Football Players

3-D rendering from a cardiac CT dataset demonstrating mild dilation of the ascending aorta.

News | Computed Tomography (CT) | January 11, 2018
Former National Football League (NFL) players are more likely to have enlarged aortas, a condition that may put them at...

Size comparison between 3-D printed prosthesis implant and a penny.

News | 3-D Printing | January 11, 2018
January 11, 2018 — Researchers using...
RSNA 2017 technical exhibits, expo floor, showing new radiology technology advances.
Feature | RSNA 2017 | January 11, 2018
January 11, 2018 — Here is a list of some of the key clinical study presentations, articles on trends and videos from
Overlay Init